GLIF phase I/II study for taxane-and-platinum-resistant endometrial carcinoma

GLIF phase I/II study for taxane-and-platinum-resistant endometrial carcinoma - GLIF study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006119

Enrollment

Registered

2011-08-08

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial carcinoma

Interventions

chemotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) age >= 20y 2) PS=0,1,2 3)Refractory or resistant to taxane and platinum (TFI<6 months) 4)life expectancy >= 3 months 5) WBC >=3000/mm3,<=12000/mm3 Neu >=1500/mm3 Plt >=100000/mm3 Hb >=8.0g/dl AST,ALT <= x2.5 Bil<= x1.5 Cr WNL 6) obtainment of informed consent

Exclusion criteria

Exclusion criteria: 1) severe allergy to drugs 2) obvious interstitial pneumonia 3) massive ascites or pleural effusion to discharge 4) severe infection 5) complication of another malignancy 6) pregnant women 7) severe mental disease 8) brain metstasis with symptoms 9) severe cardiac disease 10) severe DM 11) diarrhea 12) ileus 13) fresh intestinal bleeding 14) other severe complications 15) systemic edema 16) inadequate cases judged by a doctor

Design outcomes

Primary

Measure	Time frame
side effect anti-tumor effect	—

Secondary

Measure	Time frame
survival effect	—

Countries

Japan

Contacts

Public ContactYutaka Ueda

Osaka University Hospital Department of Obstetrics and Gynecology

ZVF03563@nifty.ne.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026